[Skip to Content]
[Skip to Content Landing]
Article
May 1963

Intrathecal Aminopterin Therapy of Meningeal Leukemia

Author Affiliations

BETHESDA, MD.

From the Medicine Branch, National Cancer Institute, National Institutes of Health.

Arch Intern Med. 1963;111(5):620-630. doi:10.1001/archinte.1963.03620290086011
Abstract

Meningeal leukemia is an important complication of acute leukemia.3 While chemotherapy has resulted in prolongation of survival,4 the effective antimetabolites do not reach therapeutic levels in the cerebrospinal fluid.5,6 As a result, meningeal leukemia has become the major therapeutic problem in patients with acute leukemia in remission, as well as being a serious complication encountered in patients with active leukemia.3

Intrathecal methotrexate (Amethopterin) has been used for the treatment of meningeal leukemia.7-9 At dosages usually employed, this therapy has often been adequate to control symptoms. However, in cases which do not respond, further increments in dosage have been limited by concern regarding neurotoxicity. Wollner et al. described seizures in dogs following 1.0-1.5 mg. per kilogram of methotrexate administered by cisternal injection.10 Moreover, neurotoxicity of folic acid antagonists related to the quantity of pteroylglutamic acid, not to the antifolic activity of the compound.10 Therefore,

First Page Preview View Large
First page PDF preview
First page PDF preview
×